Intriguingly, the CML-iPSCs were insensitive to imatinib, while CML-iPSC-derived hematopoietic cells recovered the sensitivity to imatinib with the exception of CD34+38−90+45+ immature cells which remained resistant, possibly in line with what is observed in patients. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.